Cryo-Cell is a private cord blood and cord tissue bank. The company's core service is collecting, processing, and storing umbilical cord blood and cord tissue stem cells at birth, so families have those cells available for potential future medical use — primarily to treat diseases like leukemia and other conditions where stem cell transplants are an accepted therapy, covering roughly 80 known diseases today. Cryo-Cell markets directly to expectant parents via online advertising, a national field sales team, and referrals from OB/GYNs and other healthcare providers. The business model has two revenue components: a one-time enrollment and processing fee at collection, and ongoing annual storage fees (or prepaid multi-year plans recognized as deferred revenue over time). Once enrolled, families tend to keep paying storage fees, creating a large, predictable recurring revenue base. A notable legacy liability is Cryo-Cell's Revenue Sharing Agreements, entered before 2002, under which the company shares a percentage of storage revenues from Florida and Texas with early investors in perpetuity — treated as interest expense and an ongoing drag on earnings. Beyond core storage, Cryo-Cell operates two smaller businesses: manufacturing its proprietary PrepaCyte CB processing technology for sale to cell labs, and a public cord blood bank listed on the NMDP registry. Two incremental growth initiatives are underway: ExtraVault, a third-party biorepository service for biopharma companies leveraging existing cryogenic infrastructure, and international licensing agreements with affiliates across Central America.